<DOC>
	<DOCNO>NCT00707304</DOCNO>
	<brief_summary>The purpose study determine whether talactoferrin improve overall survival patient non-small cell lung cancer ( NSCLC ) previously treat two regimen .</brief_summary>
	<brief_title>Safety Efficacy Talactoferrin Previously Treated Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB IV NSCLC Failed least 2 prior systemic anticancer regimen advance metastatic NSCLC At least one target lesion unirradiated measurable RECIST Adequate hematologic , renal hepatic function ECOG 0 , 1 , 2 Able understand sign Informed Consent Presence brain metastasis , unless patient receive brain irradiation , include adequate stereotactic radiosurgery , least 4 week prior randomization , stable , asymptomatic , steroid least 3 week prior randomization Any gastrointestinal tract disease medical condition result inability take oral medication History malignancy except : ( ) adequately treat basal squamous cell carcinoma skin ; ( ii ) curatively treat , ) situ carcinoma uterine cervix , b ) prostate cancer , c ) superficial bladder cancer ; ( iii ) curatively treat solid tumor evidence disease â‰¥ 5 year Uncontrolled ischemic heart disease , uncontrolled symptomatic congestive heart failure Serious active infection Psychiatric illness/ social situation would limit study compliance Other uncontrolled serious chronic disease condition investigator 's opinion could affect compliance followup protocol Concurrent radiotherapy site radiotherapy within 4 week prior randomization previous radiotherapy target lesion site ( site follow determination response ) Known HIV positive active antiretroviral therapy Known Hepatitis B surface antigen positive hepatitis C positive Receipt investigational medication within 4 week prior randomization Pregnant lactating patient , fertile female patient positive pregnancy test , fertile female patient unwilling use adequate contraception treatment 30 day completion treatment Sexually active male patient unwilling practice contraception participate study 30 day completion treatment Legal incapacity limit legal capacity , unless authorization grant legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Talactoferrin</keyword>
	<keyword>Dendritic Cell Recruiter Activator</keyword>
	<keyword>Immunomodulatory agent</keyword>
</DOC>